Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Toripalimab-tpzi
Indication/Tumor Type Advanced Solid Tumor
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive Advanced Solid Tumor predicted - sensitive Toripalimab-tpzi Phase I Actionable In a Phase I trial, patients with CD274 (PD-L1)-positive (membrane staining in 1% or more of tumor cells, n=16) advanced solid tumors demonstrated improved objective response rate (ORR) (43.8% vs 0%, p=0.0081) and progression-free survival (HR=0.36, p=0.034) compared to CD274 (PD-L1)-negative (n=12) patients in response to Loqtorz (toripalimab-tpzi) treatment, with an ORR of 57.1% in CD274 (PD-L1)-high (membrane staining in >50% of tumor cells, n=7) patients (PMID: 30642373; NCT02836795). 30642373
PubMed Id Reference Title Details
(30642373) Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Full reference...